Biopharma - MarketMinute

Healthcare

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of

Biopharma

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a

PolyPid

PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA

Jerusalem, Israel – December 3, 2025 – PolyPid Ltd. (NASDAQ: PYPD) witnessed a significant surge in its stock price today, gaining 3.4% following the announcement of supportive feedback from the U.S. Food and Drug Administration (FDA) regarding its pre-New Drug Application (NDA) meeting for D-PLEX100. This crucial regulatory milestone de-risks

Sarepta Therapeutics

Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial

Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage clinical trial. The biopharmaceutical company revealed that its Phase 3 ESSENCE study, evaluating the efficacy of its Duchenne muscular dystrophy (DMD) therapies Amondys

Thermo Fisher Scientific

Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism

Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent strategic developments. This significant uptick reflects investor confidence in the life sciences giant's aggressive expansion into

Aytu BioPharma

Aytu BioPharma's Q4 2025 Earnings: Anticipation Mounts Ahead of Key EXXUA Launch

NEW YORK, NY – September 23, 2025 – As the trading day concludes, all eyes in the biopharmaceutical sector are turning to Aytu BioPharma (NASDAQ: AYTU), which is poised to release its fiscal fourth-quarter and full-year 2025 operational and financial results after market close today. Investors and analysts are keenly awaiting these